Once a Week, Twice a Week, or Daily? What the Half-Life Math Says About GLP-1 Microdose Frequency

A man on a low weekly dose of semaglutide notices a rhythm. Injection day is Sunday. Monday and Tuesday he eats like a bird and feels a little queasy by mid-afternoon. Thursday he is fine. By Saturday evening he is standing in front of the open fridge again, and Sunday's injection resets the week. He has read that the drug has a seven-day half-life and wonders, reasonably, whether two half-sized injections would iron the week out. His prescriber has never been asked and is not sure either.

The question has a real answer, and it comes in two parts. The pharmacokinetics part is straightforward and can be modelled: dividing a dose leaves the average drug level and the time to steady state untouched, and shrinks the swing between the post-injection peak and the pre-injection trough. For a seven-day half-life that swing goes from roughly 1.4 to 1 on a weekly schedule to about 1.1 to 1 on a twice-weekly one. The clinical part is much thinner. No published trial has given injected semaglutide or tirzepatide on any interval other than weekly, so whether a smaller swing means a smoother week is an inference from dose-response data, not a measured result. And the practical part cuts the other way: a microdose divided into daily injections becomes a volume too small to measure honestly on a standard syringe.

This article walks through the model, shows the curves, lays out the evidence that peaks matter for tolerability, works the measurement arithmetic, and ends with a comparison table and the reasons this remains a prescriber's decision.

What does splitting a weekly GLP-1 dose actually change in the blood?

Splitting a weekly dose changes the shape of the concentration curve and nothing about its average height. That follows from a basic property of drugs cleared by first-order kinetics, which semaglutide and tirzepatide both are: the average concentration at steady state equals the dosing rate divided by clearance. Give 0.25 mg per week as one injection or as seven, and the dosing rate is 0.25 mg per week either way, so the average level over any full week is the same. The body does not care how the week's dose was packaged. It cares how much arrived and how fast it leaves.

What the package does decide is how far the level rises after each injection and how far it falls before the next. The chart below is a one-compartment model with first-order absorption, using a seven-day elimination half-life and a time to peak of about two days, which matches the Ozempic prescribing information's figures of a roughly one-week half-life and a one-to-three-day time to maximum concentration. All three lines deliver the same total dose each week. The weekly line climbs to a peak around day two after each injection and sags to a trough just before the next one. The twice-weekly line has half the amplitude. The daily line looks like a ramp with a faint ripple on it.

Two things stand out in the model. The weekly swing is smaller than the half-life alone would suggest. A drug injected as a bolus with a seven-day half-life would fall to exactly half its peak by the next dose, a 2 to 1 ratio. Because subcutaneous semaglutide is absorbed slowly over the first few days, the peak is blunted and the ratio comes out closer to 1.4 to 1. And all three lines reach the same plateau at the same time, which is the subject of the next section.

Does injecting more often reach steady state faster?

No. The time a drug takes to reach steady state depends on its elimination half-life and on nothing else in the schedule. After one half-life of continuous dosing the level is at 50 percent of its eventual plateau, after two it is at 75 percent, after three at 87.5, after four at about 94, and after five at about 97. Those fractions are the same whether the drug arrives in one weekly injection or seven daily ones, because they describe how quickly the body's elimination catches up with the input, not how the input is chopped. For semaglutide's seven-day half-life that is four to five weeks; the Ozempic prescribing information says exactly that. For tirzepatide's five-day half-life it is three to four weeks, and the Mounjaro label puts it at four weeks.

This is why the first month of any protocol feels different from the third regardless of schedule, and why the weekly-average line in the chart below is the same for a weekly and a split regimen. It is also why a person who feels nothing in week one and something in week three has not built up a tolerance to the drug or suddenly become sensitive to it. They have simply reached 85 percent of the exposure they were always heading for. The only way to arrive sooner is a loading dose larger than the maintenance dose, which trades a faster arrival for a higher initial peak and which no GLP-1 label uses; every one of them goes the other way, starting low and stepping up precisely to keep the early peaks small.

Why does the dosing interval matter more for tirzepatide than for semaglutide?

The interval matters more for tirzepatide because its half-life is shorter, so more of each dose has been cleared by the time the next one arrives. The Mounjaro and Zepbound prescribing information give tirzepatide a half-life of about five days, against about seven for semaglutide. Over a seven-day interval that difference compounds: semaglutide retains half of a bolus at the trough, tirzepatide about 38 percent. In the same absorption-adjusted model, weekly tirzepatide swings from about 121 percent of the average at the peak to 70 percent at the trough, a ratio near 1.7 to 1, while weekly semaglutide runs 112 to 80, or 1.4 to 1.

Splitting the dose narrows both, and it narrows tirzepatide more in absolute terms. Twice-weekly tirzepatide comes down to roughly 106 to 89 percent, or 1.2 to 1; twice-weekly semaglutide to 103 to 94, or 1.1 to 1. That is the strongest version of the pharmacokinetic case for a split schedule: the molecule with the bigger weekly swing has the most to gain from a smaller one. It cuts both ways, though. The shorter half-life also means tirzepatide reaches steady state about a week sooner, clears about a week sooner after stopping, and has a shorter labelled catch-up window for a missed dose, four days against semaglutide's five. A person who wants a steadier week from tirzepatide is asking for something the molecule's own kinetics make harder to supply on a weekly schedule.

Would a flatter GLP-1 curve mean fewer side effects?

Probably some, and nobody has measured it. The reason to think peaks matter is that gastrointestinal side effects track dose in every trial programme in the class. In SUSTAIN 1, Sorli and colleagues reported nausea in 8 percent of people on placebo, 20 percent on semaglutide 0.5 mg weekly, and 24 percent on 1.0 mg. In STEP 1, Wilding and colleagues reported nausea in 44 percent on 2.4 mg against 17 percent on placebo. A higher weekly dose means a higher peak as well as a higher average, so those figures do not on their own separate the two. The timing data do. Wharton and colleagues analysed the STEP 1 tolerability record in 2022 and found that nausea, vomiting, and diarrhoea clustered in the weeks after each dose step, when concentration was climbing to a new high, and faded between steps once the level settled. Side effects follow the rise, not just the height.

The one head-to-head comparison of a peaky and a flat profile with the same molecule comes from an older drug. In the DURATION-1 trial, Drucker and colleagues gave exenatide either as the twice-daily immediate-release injection, which produces a sharp spike after every dose, or as the once-weekly extended-release form, which trickles the drug out from microspheres at a nearly constant rate. The weekly form produced nausea in 26 percent of participants and the twice-daily form in 35 percent, with the same or better glucose control. That is the flat-curve hypothesis confirmed, but in the opposite direction to the one microdosers are asking about: there, the flatter profile was the less frequent one, because the formulation did the smoothing. Frequency by itself is not the variable; the swing is.

Two cautions before anyone extrapolates. Nauck and colleagues showed in 2011 that the gastric emptying effect of GLP-1 fades quickly under continuous exposure, and Umapathysivam and colleagues confirmed in 2014 that steady stimulation slows the stomach much less than intermittent stimulation. The body adapts to whatever level it is held at, which is why side effects on a stable dose fade over weeks regardless of interval, and why the benefit of a smaller swing may be largest in the escalation phase and modest afterward. And the modelled swing for weekly semaglutide, 1.4 to 1, is not large. A person at a stable microdose who feels queasy on day two and hungry on day seven is describing that swing; a person who feels fine all week is describing the adaptation.

What is the practical limit on splitting a GLP-1 microdose?

The syringe. A microdose is already a small volume, and every division makes each injection smaller. Take a common example: semaglutide reconstituted to 2.5 mg per mL and a weekly dose of 0.25 mg. That is 0.1 mL, or 10 units on a U-100 insulin syringe, a volume most people can draw to within half a unit. Split into two injections it becomes 5 units. Split across seven days it becomes 0.014 mL, about 1.4 units, and the half-unit gradations on a standard syringe simply do not resolve that. A reading that is consistently half a unit high or low is a 5 percent error on the weekly dose, a 10 percent error on the twice-weekly dose, and about a 36 percent error on the daily dose.

That arithmetic reverses the pharmacokinetic picture. Daily dosing gives the flattest curve on paper and the noisiest dose in practice, because a third of the intended amount is inside the measurement error of every injection. Twice-weekly splitting keeps the volume in readable territory and captures most of the smoothing: the swing drops from 1.4 to 1 to 1.1 to 1, and the further drop to a truly flat line with daily dosing is small by comparison. The other costs are less dramatic but real. More injections means more site rotation to manage, more needles, and a reconstituted vial that is opened more often and drawn from more times. A schedule that requires a different reconstitution strength to make the volume readable is a change the pharmacist needs to be part of.

How do weekly, split, and daily GLP-1 schedules compare?

Weekly dosing is the only schedule with trial evidence and the only one on the label; a twice-weekly split trades four extra injections a month and double the measurement error for a swing about a third the size; daily dosing of a true microdose trades a flat curve for a dose that cannot be measured reliably. The table gathers the numbers from the sections above. The averages, steady-state timing, and trial-evidence rows do not change across the columns, which is most of the answer: the schedule is a tolerability lever, not an efficacy lever, and a small one.

The row that should end most conversations is the last one. Daily injected semaglutide has never been trialled, and the one daily semaglutide product that exists, oral Rybelsus, is a different formulation with its own absorption problem to solve and its own trial programme; its 14 mg tablet produces exposure comparable to 1.0 mg injected weekly, which shows daily exposure to the molecule is an accepted paradigm, not that dividing an injection is. Liraglutide, dosed once daily by injection in the SCALE trials, has a 13-hour half-life and needs daily dosing to stay in range at all. Neither is evidence about a divided weekly molecule.

Who decides the GLP-1 injection schedule, and what should the conversation include?

The prescriber decides, because the interval is part of the prescription and because a microdose is already an off-label regimen the prescriber has chosen to write and to monitor. A second off-label change layered on top without them removes their ability to interpret what happens next: a bout of nausea, a change in appetite, or a plateau can no longer be read against a known schedule. The pharmacist belongs in the conversation too, since a split schedule changes how many doses a vial provides, how many times a reconstituted vial is entered, how long it sits open in the fridge, and how the label's missed-dose rules, five days for semaglutide and four for tirzepatide, apply when doses are 3.5 days apart rather than seven.

The conversation has a clear shape. The case for a split rests on a weekly pattern the person can actually describe: queasiness on days one and two and hunger on days six and seven, at a dose that is otherwise right. The case against rests on the absence of trial data, the measurement arithmetic, and the adaptation that tends to flatten side effects on any stable dose within a month or two. A prescriber who hears a clear day-two, day-seven pattern at a stable dose has something to weigh; one who hears it in week three of a new dose is more likely to wait for the stomach to adapt. Either way the person arrives with a mechanism, a number, and a question rather than a change already made.

The average is fixed by the dose. The swing is fixed by the schedule. The syringe fixes the rest.

Dividing a weekly GLP-1 dose is a question with an unusually clean answer on paper. The total dose sets the average level and the half-life sets how long it takes to get there, and neither moves when the dose is split. The schedule sets only the swing, which for weekly semaglutide is about 1.4 to 1, for weekly tirzepatide about 1.7 to 1, and for either molecule on a twice-weekly split close to 1.1 or 1.2 to 1. The dose-response and timing data say peaks probably matter for nausea, an old exenatide trial says a flatter profile is better tolerated, and no trial has tested the specific change anyone is asking about. Below that sits the practical floor: a microdose divided far enough becomes a volume that a standard syringe cannot measure, and the flat curve on paper turns into a noisy dose in the hand. All of that is worth bringing to a prescriber. None of it is worth doing alone.

Frequently asked questions

Clinical references

1. Novo Nordisk. Ozempic (semaglutide) injection: prescribing information, clinical pharmacology (half-life, time to maximum concentration, time to steady state) and dosage and administration. US Food and Drug Administration; 2017, with subsequent revisions.
2. Novo Nordisk. Wegovy (semaglutide) injection 2.4 mg: prescribing information. US Food and Drug Administration; 2021, with subsequent revisions.
3. Eli Lilly. Mounjaro (tirzepatide) injection: prescribing information, clinical pharmacology and dosage and administration. US Food and Drug Administration; 2022, with subsequent revisions.
4. Eli Lilly. Zepbound (tirzepatide) injection: prescribing information. US Food and Drug Administration; 2023, with subsequent revisions.
5. Kapitza C, Nosek L, Jensen L, Hartvig H, Jensen CB, Flint A. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. Journal of Clinical Pharmacology. 2015;55(5):497-504.
6. Overgaard RV, Delff PH, Petri KCC, Anderson TW, Flint A, Ingwersen SH. Population pharmacokinetics of semaglutide for type 2 diabetes. Diabetes Therapy. 2019;10(2):649-662.
7. Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes and Endocrinology. 2017;5(4):251-260.
8. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989-1002.
9. Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes, Obesity and Metabolism. 2022;24(1):94-105.
10. Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study (DURATION-1). Lancet. 2008;372(9645):1240-1250.
11. Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes. 2011;60(5):1561-1565.
12. Umapathysivam MM, Lee MY, Jones KL, et al. Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia. Diabetes. 2014;63(2):785-790.
13. Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019;42(9):1724-1732.
14. Novo Nordisk. Rybelsus (semaglutide) tablets: prescribing information, clinical pharmacology. US Food and Drug Administration; 2019, with subsequent revisions.
15. Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management (SCALE Obesity and Prediabetes). New England Journal of Medicine. 2015;373(1):11-22.
16. Rowland M, Tozer TN. Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications. 4th edition. Lippincott Williams and Wilkins; 2011. Chapters on multiple-dose regimens and accumulation.